Is empagliflozin (Jardiance) safe in patients with frequent urinary tract infections?

Jardiance Can Be Used in Patients with Frequent UTIs, But Requires Careful Monitoring

Empagliflozin (Jardiance) is not contraindicated in patients with frequent urinary tract infections, but these patients require heightened surveillance and prompt treatment of infections when they occur. The drug increases UTI risk modestly, but this must be weighed against its substantial cardiovascular and renal benefits.

Understanding the Risk Profile

The FDA label for Jardiance explicitly warns about increased risk of serious urinary tract infections, including urosepsis and pyelonephritis requiring hospitalization 1. However, the actual magnitude of this risk is relatively modest based on pooled safety data.

Key Safety Data:

• In pooled trials of nearly 10,000 patients, UTI incidence was similar between empagliflozin (9.27 per 100 patient-years) and placebo (9.70 per 100 patient-years) 2
• Serious UTIs requiring hospitalization occurred in only 0.2-0.4% of empagliflozin-treated patients 3
• History of chronic or recurrent UTIs was identified as a specific risk factor for developing UTIs during treatment 1, 2

Clinical Decision Framework

When to Proceed with Caution (Not Contraindicated):

Patients with recurrent UTIs can receive Jardiance if:

• UTIs are uncomplicated (no structural abnormalities, no immunosuppression)
• Patient can recognize UTI symptoms early
• Rapid access to medical care is available
• The cardiovascular/renal benefits outweigh infection risks (established cardiovascular disease, heart failure, or chronic kidney disease)

Recent guidelines emphasize that SGLT2 inhibitors like empagliflozin provide major mortality and morbidity benefits in patients with type 2 diabetes and cardiovascular disease, heart failure, or CKD 4, 5, 6. These benefits often justify accepting a modest increase in manageable infections.

Risk Mitigation Strategy:

1. Pre-treatment assessment:

   • Document baseline UTI frequency and severity
   • Identify any anatomical abnormalities (cystocele, bladder diverticula, obstruction) that would classify UTIs as "complicated" 7
   • Ensure diabetes is reasonably controlled (uncontrolled hyperglycemia independently increases infection risk) 4

2. Patient education is critical:

   • Teach recognition of UTI symptoms (dysuria, frequency, urgency, suprapubic pain)
   • Instruct immediate discontinuation and medical contact if signs of serious infection develop (fever, flank pain, systemic symptoms) 1
   • Emphasize adequate hydration and post-coital voiding 7, 8

3. Monitoring protocol:

   • Obtain urine culture at first sign of symptomatic UTI (not surveillance cultures in asymptomatic patients) 8, 9
   • Treat promptly with culture-directed antibiotics 8
   • Consider temporary discontinuation during acute UTI treatment, especially if severe

When to Avoid or Discontinue:

Do not use Jardiance in patients with:

• Active urosepsis or pyelonephritis (treat infection first, then reassess)
• Complicated UTI risk factors: indwelling catheters, urinary obstruction, immunosuppression, pregnancy 7, 8
• Inability to recognize or report symptoms promptly
• Recurrent pyelonephritis (suggests complicated etiology requiring workup) 7, 8

Important Nuances

The mechanism matters: While SGLT2 inhibitors increase urinary glucose (theoretically promoting bacterial growth), emerging evidence suggests empagliflozin may actually modulate kidney immune responses favorably 10. Some in vitro data even shows direct antibacterial effects against E. coli 11. This may explain why clinical trial UTI rates are not dramatically elevated despite persistent glucosuria.

Gender considerations: UTIs occur more frequently in women taking empagliflozin (16-18% in females vs 3-4% in males over 24 weeks) 1. Female patients with recurrent UTIs warrant particularly careful counseling.

Genital infections are more common than UTIs: Genital mycotic infections occur in 3.7-4.1% of empagliflozin-treated patients versus 0.9% with placebo 1. These are typically mild and easily treated but should be discussed as part of informed consent.

The Bottom Line

For patients with established cardiovascular disease, heart failure, or CKD who have frequent but uncomplicated UTIs, the mortality and morbidity benefits of empagliflozin generally outweigh the modest increase in manageable urinary infections 4, 5, 12. The key is proper patient selection, thorough education, and a clear plan for rapid evaluation and treatment of breakthrough infections. Patients who cannot reliably recognize symptoms or access care quickly are poor candidates regardless of their cardiovascular benefit potential.